Protara net loss widens to $21.7 million in Q2 FY26; R&D expenses rise to $17 million

Reuters2026/08/11 12:05

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Protara posted a 2Q 2026 net loss of $21.7 million, widening from $15 million a year earlier; loss per share was $0.36.
R&D spending climbed 57.41% to $17 million, due to higher clinical-trial costs, personnel expenses and chemistry, manufacturing and controls work.
G&A expenses rose 10.15% to $6.4 million; cash, cash equivalents and marketable debt securities totaled $161.9 million at June 30.
Protara expects to complete enrollment in the ADVANCED-2 BCG-unresponsive cohort in 4Q 2026, while redesigning ADVANCED-3 as an exploratory NMIBC trial.
It expects a STARBORN-1 update and to complete enrollment in 4Q 2026, targets a TARA-002 lymphatic malformations BLA in 2H 2027, and sees THRIVE-3 interim data in 4Q 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Protara Therapeutics Inc. published the original content used to generate this news brief on August 11, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Protara net loss widens to $21.7 million in Q2 FY26; R&D expenses rise to $17 million

You may also like

Crypto prices